^
Association details:
| Biomarker: | FLT3 N676K |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | merestinib (LY2801653) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
Published date:
11/06/2019
Excerpt:
The pt with a CR remained on merestinib monotherapy until progression at the end of cycle 4, at which point LY2874455 was added per protocol...Notably, this responder had baseline normal cytogenetics and mutations in DNMT3A (R882H), FLT3 (N676K), NPM1 (W288fs), TET2 (E227fs) and TET2 (L1231P)...Preliminary clinical data suggest that merestinib is tolerable...
DOI:
https://doi.org/10.1182/blood-2019-126224
